- Home
- JFU vs APLM Comparison
JFU vs APLM Comparison
Compare JFU & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- APLM
- Stock Information
- Founded
- JFU 2006
- APLM 2016
- Country
- JFU China
- APLM United States
- Employees
- JFU N/A
- APLM N/A
- Industry
- JFU Finance: Consumer Services
- APLM Blank Checks
- Sector
- JFU Finance
- APLM Finance
- Exchange
- JFU Nasdaq
- APLM Nasdaq
- Market Cap
- JFU 16.5M
- APLM 15.6M
- IPO Year
- JFU 2019
- APLM N/A
- Fundamental
- Price
- JFU $1.36
- APLM $0.10
- Analyst Decision
- JFU
- APLM Strong Buy
- Analyst Count
- JFU 0
- APLM 2
- Target Price
- JFU N/A
- APLM $4.25
- AVG Volume (30 Days)
- JFU 16.2K
- APLM 87.1M
- Earning Date
- JFU 11-29-2024
- APLM 08-14-2024
- Dividend Yield
- JFU N/A
- APLM N/A
- EPS Growth
- JFU N/A
- APLM N/A
- EPS
- JFU 0.09
- APLM N/A
- Revenue
- JFU $40,614,155.00
- APLM $2,101,000.00
- Revenue This Year
- JFU N/A
- APLM N/A
- Revenue Next Year
- JFU N/A
- APLM N/A
- P/E Ratio
- JFU $13.73
- APLM N/A
- Revenue Growth
- JFU N/A
- APLM 70.54
- 52 Week Low
- JFU $1.13
- APLM $0.08
- 52 Week High
- JFU $4.90
- APLM $1.23
- Technical
- Relative Strength Index (RSI)
- JFU 39.39
- APLM 40.57
- Support Level
- JFU $1.13
- APLM $0.08
- Resistance Level
- JFU $1.51
- APLM $0.36
- Average True Range (ATR)
- JFU 0.16
- APLM 0.03
- MACD
- JFU -0.02
- APLM -0.00
- Stochastic Oscillator
- JFU 34.48
- APLM 3.11
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.